Frontlight ResearchEarly access
CompletedPhase 2
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
Key facts
- Who runs it
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 106 people enrolled
- Started
- 21 Jul 2023
- Ended
- 28 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Genakumab for injection
- Colchicine
- Record updated
- 8 November 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Other criteria
- Male or female, 18 years ≤ age ≤ 75 years
- BMI ≤ 40kg/m2
- Meeting ACR 2015 preliminary criteria for the classification of acute arthritis of primary gout
- Start of acute gout flare within 3 days prior to enrolled
- History of ≥2 gout flare within 12 months prior to study start
- Baseline pain intensity ≥ 50mm on the 0-100mm visual analog scale(VAS)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
The 2 groups in the trial
- Genacumab groupTreatment being tested
Genakumab 200mg single injection
Treatment: Genakumab for injection
- cholchicine groupExisting treatment, for comparison
Colchicine 0.5mg qd po.for 12 weeks
Treatment: Colchicine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open Lable, Multi-center, Active Competitor Phase 2 Study for Evaluating Efficacy and Safety of Genakumab for Injection as First Line Therapy in Patients With Gout Flare
- Publications
- Record updated
- 8 November 2024